Analyst Ratings For Biogen (NASDAQ:BIIB)
Today, Biogen (NASDAQ:BIIB) stock received an upgrade by Mizuho from Neutral to Buy with a price target of $400.00.
There are 9 hold ratings, 14 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Biogen (NASDAQ:BIIB) is Buy (Score: 2.67) with a consensus target price of $341.82 per share, a potential 1.83% upside.
Some recent analyst ratings include
- 10/17/2017-Mizuho Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 10/17/2017-Stifel Nicolaus Upgrade from a “Hold ” rating to a ” Buy” rating.
- 10/5/2017-Royal Bank Of Canada Reiterated Rating of Hold.
- 10/5/2017-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.
- 9/21/2017-Raymond James Financial, Inc. was Downgraded by analysts at Raymond James Financial, Inc. from a “Strong-Buy ” rating to a ” Market Perform” rating. They now have a $319.00 price target on the stock, up previously from $244.28 .
- 9/20/2017-SunTrust Banks, Inc. initiated coverage with a Buy rating.
Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.25% and institutional ownership of 87.62%.
- On 7/25/2017 Susan H Alexander, EVP, sold 4,974 with an average share price of $290.01 per share and the total transaction amounting to $1,442,509.74. View SEC Filing
- On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00. View SEC Filing
- On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04. View SEC Filing
- On 5/1/2017 Michel Vounatsos, CEO, bought 1,402 with an average share price of $271.35 per share and the total transaction amounting to $380,432.70. View SEC Filing
- On 4/27/2017 Alexander J. Denner, Director, bought 73,858 with an average share price of $278.50 per share and the total transaction amounting to $20,569,453.00. View SEC Filing
- On 4/25/2017 Paul J Clancy, VP, sold 9,892 with an average share price of $290.00 per share and the total transaction amounting to $2,868,680.00. View SEC Filing
- On 4/3/2017 Alfred Sandrock, CMO, sold 1,981 with an average share price of $274.08 per share and the total transaction amounting to $542,952.48. View SEC Filing
Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at with shares trading hands.